Surf Air Mobility

FINCH THERAPEUTICS (NASDAQ: FNCH) STOCK QUOTE

Last Trade: US$11.90 10.10 561.11
Volume: 2,628
5-Day Change: 513.40%
YTD Change: 229.64%
Market Cap: US$19.160M

LATEST NEWS FROM FINCH THERAPEUTICS

BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group , Inc. (Nasdaq: FNCH) (“Finch” or the “Company”), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has provided notification to The Nasdaq Stock Market, LLC (“Nasdaq”) of its intent to delist the Company’s common stock, par value $0.001 per share (the “Common Stock”), from the Nasdaq... Read More
BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced it will effect a one-for-30 reverse stock split of its issued and outstanding common stock. Finch stockholders approved an amendment to its Amended and Restated Certificate of... Read More
SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates. “Finch has continued to execute on its strategy to advance its novel microbiome technology through... Read More
Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO effective May 15 Lance Thibault, Managing Director of Danforth Advisors, to serve as Chief Financial Officer effective May 16, 2023; Marc Blaustein to complete his time as Chief Operating Officer and principal financial officer... Read More
SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has entered into a clinical trial agreement with Brigham and Women’s Hospital for the evaluation of CP101, a Complete Consortia microbiome therapeutic, in... Read More
SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported fourth quarter and full year 2022 financial results and provided business updates. “We believe that Finch has made significant progress towards restructuring the... Read More
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets. This decision follows an assessment by Finch’s management team and board... Read More
Patient dosing underway in PRISM4 Phase 3 trial of CP101 in recurrent CDI Topline PRISM4 data anticipated in H1 2024 Anticipated cash runway into Q2 2024 SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally... Read More
SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that the company will present at the following investor conferences: Jefferies London Healthcare Conference... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced the presentation of biomarker data from PRISM-EXT, a Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI), at the American College of... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced plans to reduce its workforce by approximately 37% as part of an ongoing strategic review of its business and portfolio. This decision follows Finch’s recent... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that it will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Limited (“Takeda”).... Read More
On track to proceed with enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI in H2 2022 On track to submit IND for FIN-211 in children with autism and significant GI symptoms in Q4 2022 Additional results from PRISM-EXT Phase 2 trial of CP101 in recurrent CDI accepted for presentation at ACG 2022 Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in fireside chats at the following investor conferences: Jefferies Healthcare Conference on Friday, June... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. The... Read More
FDA lifted clinical hold on IND for CP101 Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022 $15 million drawn from new $55 million term debt facility Anticipated cash runway into Q2 2024 Corporate update call today at 8am ET Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced it will host a conference call and live webcast on Monday, May 16, 2022 at 8:00am ET to discuss updates to its development programs and other business highlights. The... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on Finch’s investigational new drug (IND) application for CP101. CP101 is the Company’s... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced plans to reduce its workforce by approximately 20%. This workforce reduction will allow the company to focus its financial resources on its recurrent C. difficile... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today reported fourth quarter and full year 2021 financial results and provided business updates. “Finch achieved many significant milestones in 2021, including new clinical data... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics” or “Company”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that it has paused enrollment in PRISM4, its Phase 3 clinical trial of CP101 in recurrent C. difficile infection (CDI) following receipt of a clinical hold... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a panel discussion at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1,... Read More
Bryan Gillis, MBA, appointed Chief Technology Officer Alka Batycky, PhD, appointed Chief Development Officer Howard Franklin, MD, MBA, appointed Senior Vice President, Late-Stage Development and GI Therapeutic Area Lead Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that the U.S. Patent and Trademark Office has issued two new patents covering the company’s FIN-211 enriched consortia microbiome product candidate in development for... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a corporate overview at the virtual 40 th Annual J.P. Morgan Healthcare Conference on Thursday, January 13,... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced the promotion of Joseph Vittiglio, JD, to Chief Business and Legal Officer. Mr. Vittiglio has more than 25 years of experience leading strategic transactions within the... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate virtually in two upcoming investor conferences: Jefferies London Healthcare Conference: Finch will... Read More
New positive topline data from 132-participant PRISM-EXT Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI) show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained through 24 weeks New data presented at ACG annual meeting from PRISM3 Phase 2 trial of CP101 in recurrent CDI show a statistically significant improvement in sustained clinical cure and a safety profile... Read More
Zain Kassam, MD, MPH to step down as Chief Medical Officer (CMO) and will serve as a special advisor to the company Debra Silberg, MD, PhD to transition from clinical advisor to interim CMO Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological... Read More
New data from 132-participant PRISM-EXT Phase 2 open-label trial show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained through 24 weeks and a safety profile consistent with previously reported data Aggregated 88.2% sustained clinical cure rate shown through 8 weeks following last dose in post-hoc analysis of participants that received up to two doses of CP101 in PRISM3 and PRISM-EXT trials... Read More
New data from PRISM3 Phase 2 trial show CP101 demonstrated statistically significant efficacy for prevention of recurrent C. difficile infection and a favorable safety profile through 24 weeks Additional PRISM3 microbiome data show CP101 engraftment leads to an increase in intestinal microbiome diversity and sustained clinical cure Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Tuesday, October 19, 2021. The... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that Samuel Allen (Al) Hamood has joined Finch’s Board of Directors. Mr. Hamood is an accomplished executive with over 30 years of experience in finance, business... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced the appointment of Marc Blaustein as Chief Operating Officer. Mr. Blaustein is a seasoned biopharmaceutical executive with more than 20 years of experience building and... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright 23 rd Annual Global Investment Conference being held September... Read More
Takeda to accelerate leadership role in advancing FIN-524/TAK-524 ulcerative colitis development program Topline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in open label PRISM-EXT trial expected in H2 2021 Continued progress advancing development programs, with clinical data across multiple programs anticipated in 2022 Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”)... Read More
Finch to transfer FIN-524 program to Takeda for clinical development Finch and Takeda to continue discovery efforts targeting Crohn’s disease Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Takeda Pharmaceutical... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that it was added to the Russell 2000 and Russell 3000 Indexes as part of the 2021 Russell indexes annual reconstitution that took effect after the market close on June... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in two upcoming virtual investor conferences: Jefferies Virtual Healthcare Conference: Finch will... Read More
Completed upsized IPO, raising $130.8 million in gross proceeds Topline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in PRISM-EXT expected in H2 2021 Strengthened leadership team with the appointment of Susan E. Graf to Board of Directors, Michelle Rose, PhD, as Chief Regulatory Officer, David Pugatch, MD, as Vice President of Clinical Development, and Joseph Vittiglio, JD, as General... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021 at 2:45 pm... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Susan E. Graf has joined Finch’s Board of Directors and will serve as Chair of the Audit Committee. Ms. Graf is an accomplished biopharma executive with more than 25... Read More
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a fireside chat and panel discussion at the virtual Jefferies Microbiome-Based Therapeutics Summit on... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS